[go: up one dir, main page]

PE20191044A1 - Composicion farmaceutica - Google Patents

Composicion farmaceutica

Info

Publication number
PE20191044A1
PE20191044A1 PE2019000675A PE2019000675A PE20191044A1 PE 20191044 A1 PE20191044 A1 PE 20191044A1 PE 2019000675 A PE2019000675 A PE 2019000675A PE 2019000675 A PE2019000675 A PE 2019000675A PE 20191044 A1 PE20191044 A1 PE 20191044A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
composition
weight
component
amount
Prior art date
Application number
PE2019000675A
Other languages
English (en)
Inventor
Stuart Corr
Timothy James Noakes
Original Assignee
Mexichem Fluor Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59997387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20191044(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB1615908.9A external-priority patent/GB2554088A/en
Priority claimed from GBGB1620515.5A external-priority patent/GB201620515D0/en
Application filed by Mexichem Fluor Sa De Cv filed Critical Mexichem Fluor Sa De Cv
Publication of PE20191044A1 publication Critical patent/PE20191044A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: i) UN COMPONENTE DE FARMACO QUE COMPRENDE BECLOMETASONA DIPROPIONATO Y FORMOTEROL FUMARATO DIHIDRATO, EN UNA CANTIDAD DE 0.05 A 1.5% EN PESO DEL PESO TOTAL DE LA COMPOSICION; ii) UN COMPONENTE PROPULSOR QUE COMPRENDE 1,1-DIFLUOROETANO (HFA-152a) EN UNA CANTIDAD DE 97.5 A 99.95% EN PESO DEL PESO TOTAL DE LA COMPOSICION FARMACEUTICA; Y iii) GLICEROL; DONDE DICHO COMPONENTE DE FARMACO COMPRENDE ADICIONALMENTE UN ANTAGONISTA MUSCARINICO DE ACCION PROLONGADA COMO EL BROMURO DE GLICOPIRRONIO. DICHA COMPOSICION COMPRENDE ADEMAS UN EXCIPIENTE POLAR COMO EL ETANOL
PE2019000675A 2016-09-19 2017-09-18 Composicion farmaceutica PE20191044A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1615908.9A GB2554088A (en) 2016-09-19 2016-09-19 Pharmaceautical composition
GBGB1620515.5A GB201620515D0 (en) 2016-12-02 2016-12-02 Pharmaceutical composition
PCT/GB2017/052762 WO2018051131A1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
PE20191044A1 true PE20191044A1 (es) 2019-08-06

Family

ID=59997387

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000675A PE20191044A1 (es) 2016-09-19 2017-09-18 Composicion farmaceutica

Country Status (19)

Country Link
US (3) US20190388436A1 (es)
EP (3) EP3515451B2 (es)
JP (2) JP6781832B2 (es)
KR (1) KR102279445B1 (es)
CN (3) CN113069417A (es)
AU (2) AU2017328908B2 (es)
CA (1) CA3037257C (es)
CO (1) CO2019002555A2 (es)
EA (1) EA201990501A1 (es)
ES (1) ES2841649T5 (es)
GE (1) GEP20217240B (es)
IL (1) IL265349B2 (es)
MX (1) MX2019003103A (es)
MY (2) MY210122A (es)
PE (1) PE20191044A1 (es)
PH (1) PH12019500577B1 (es)
UA (1) UA124240C2 (es)
WO (1) WO2018051131A1 (es)
ZA (1) ZA201902052B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190374519A1 (en) * 2016-09-19 2019-12-12 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
WO2020100040A1 (en) * 2018-11-12 2020-05-22 3M Innovative Properties Company Umeclidinium and vilanterol formulation and inhaler
WO2020152548A1 (en) * 2019-01-24 2020-07-30 Glenmark Pharmaceuticals Limited Stable aerosol inhalation compositions of formoterol
GB2584686A (en) * 2019-06-11 2020-12-16 Mexichem Fluor Sa De Cv Methods
GB2586477A (en) * 2019-08-20 2021-02-24 Mexichem Fluor Sa De Cv Composition and method
KR102835735B1 (ko) * 2019-12-02 2025-07-21 키에시 파르마슈티시 엣스. 피. 에이. 가압 정량 흡입기를 위한 스테인리스 스틸 캔
PE20221867A1 (es) * 2020-01-28 2022-12-02 Chiesi Farm Spa Inhaladores de dosis medida presurizada que comprenden una formulacion farmaceutica amortiguada
AU2021223587A1 (en) 2020-02-20 2022-09-29 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69324161T2 (de) * 1992-12-09 1999-10-28 Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield Stabilisierte medizinische aerosollösungen
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
KR100589926B1 (ko) 1997-09-29 2006-06-15 넥타르 테라퓨틱스 천공된 미립자 및 사용 방법
CN1158996C (zh) * 1998-07-24 2004-07-28 杰格研究股份公司 药用气溶胶制剂
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
CA2510043A1 (en) * 2002-12-16 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing hfc solution formulations
EP1982709A1 (en) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
US20100008997A1 (en) * 2007-10-25 2010-01-14 Revalesio Corporation Compositions and methods for treating asthma and other lung disorders
CN103269694A (zh) * 2010-10-12 2013-08-28 西普拉有限公司 药物组合物
EP2749280A3 (en) * 2011-02-17 2014-08-20 Cipla Limited Combination of glycopyrronium and formoterol
GB201108039D0 (en) * 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
JP2016503390A (ja) * 2012-10-23 2016-02-04 シプラ・リミテッド 医薬組成物
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
EP3383366B2 (en) * 2015-12-04 2024-06-05 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
JP6781828B2 (ja) * 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
US11260052B2 (en) * 2016-09-19 2022-03-01 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
US20190374519A1 (en) * 2016-09-19 2019-12-12 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
PE20191043A1 (es) * 2016-09-19 2019-08-06 Mexichem Fluor Sa De Cv Composicion farmaceutica

Also Published As

Publication number Publication date
CO2019002555A2 (es) 2020-02-18
AU2020202651B2 (en) 2021-05-20
PH12019500577B1 (en) 2023-09-08
IL265349A (en) 2019-05-30
KR20190084945A (ko) 2019-07-17
EP3515451B1 (en) 2020-11-04
NZ752434A (en) 2020-11-27
CN116898804A (zh) 2023-10-20
BR112019005113A2 (pt) 2019-06-04
ES2841649T3 (es) 2021-07-08
WO2018051131A1 (en) 2018-03-22
US20200016174A1 (en) 2020-01-16
US20200016175A1 (en) 2020-01-16
IL265349B2 (en) 2023-03-01
UA124240C2 (uk) 2021-08-11
EP3610877A1 (en) 2020-02-19
US20190388436A1 (en) 2019-12-26
MY210122A (en) 2025-08-28
EP3515451A1 (en) 2019-07-31
JP2020109107A (ja) 2020-07-16
AU2020202651A1 (en) 2020-05-14
EP3515451B2 (en) 2023-10-04
EP3607951A1 (en) 2020-02-12
JP6980050B2 (ja) 2021-12-15
ES2841649T5 (es) 2024-04-24
PH12019500577A1 (en) 2019-07-24
ZA201902052B (en) 2024-09-25
IL265349B (en) 2022-11-01
CN113069417A (zh) 2021-07-06
CA3037257A1 (en) 2018-03-22
CN109789151A (zh) 2019-05-21
AU2017328908A1 (en) 2019-05-02
AU2017328908B2 (en) 2020-04-02
KR102279445B1 (ko) 2021-07-22
GEP20217240B (en) 2021-03-25
JP2019529432A (ja) 2019-10-17
MX2019003103A (es) 2019-08-01
EA201990501A1 (ru) 2019-09-30
AU2020202651C1 (en) 2021-09-16
JP6781832B2 (ja) 2020-11-04
CA3037257C (en) 2022-01-04
MY202030A (en) 2024-03-29

Similar Documents

Publication Publication Date Title
PE20191044A1 (es) Composicion farmaceutica
PE20191043A1 (es) Composicion farmaceutica
CO2019000613A2 (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
MX2018005708A (es) Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7.
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
MX2019011701A (es) Composiciones de canabinoide y usos.
UY35293A (es) Isotiazoles sustituidos con amino
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
CL2018000363A1 (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana.
MX2020004810A (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000007A (es) Pirazolpiridinas sustituidas
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
NI201700077A (es) Ácidos piridil-cicloalquil-carboxílico sustituidos, composiciones que los contienen y usos de los mismos.
MX2017016862A (es) Composicion farmaceutica estable para administracion oral.
EA201890075A1 (ru) Инъецируемые фармацевтические композиции лефамулина
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
BR112016013974A2 (pt) Composto, composição farmacêutica, uso da composição farmacêutica e uso do composto
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto